Literature DB >> 6475838

Gastrin-releasing peptide immunoreactivity in intestinal carcinoids.

D G Bostwick, K A Roth, J D Barchas, K G Bensch.   

Abstract

Human neuroendocrine tumors are known to demonstrate immunoreactivity to the amphibian peptide bombesin. The recent observation that gastrin-releasing peptide (GRP), a 27 amino acid peptide first isolated from porcine intestine, may be the mammalian analog of bombesin led us to look for this peptide in intestinal carcinoid tumors. Formalin-fixed tissues from 20 of these tumors were examined by the immunoperoxidase technic, using specific antisera to the GRP molecule (1-27) and the GRP fragment (1-16). Intense diffuse cytoplasmic immunoreactivity was observed in carcinoids from the small intestine (7/10), appendix (4/5), and colon (1/5). In each positive case, the pattern of staining for GRP (1-16) and GRP (1-27) was identical. These findings indicate that bombesin-like immunoreactivity in human intestinal carcinoid tumors is attributable to GRP-like molecules and that GRP is a useful marker for neuroendocrine differentiation.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6475838     DOI: 10.1093/ajcp/82.4.428

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  3 in total

1.  Gastrin releasing peptide GRP(14-27) in human breast cancer cells and in small cell lung cancer.

Authors:  A J Vangsted; E V Andersen; L Nedergaard; J Zeuthen
Journal:  Breast Cancer Res Treat       Date:  1991-10       Impact factor: 4.872

Review 2.  Achlorhydria: hypergastrinaemia: carcinoids--a flawed hypothesis?

Authors:  J Penston; K G Wormsley
Journal:  Gut       Date:  1987-04       Impact factor: 23.059

3.  Gastrin releasing peptide and gastrin releasing peptide receptor expression in gastrointestinal carcinoid tumours.

Authors:  N Scott; E Millward; E J Cartwright; S R Preston; P L Coletta
Journal:  J Clin Pathol       Date:  2004-02       Impact factor: 3.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.